ClinicalTrials.gg
No longer availableNCT04878718Updated Jun 8, 2025

Vancomycin and Fecal Microbiota Transplant in a Single Patient With Autism Spectrum Disorder

An expanded access record providing Fecal Microbiota Transplant; Vancomycin in Autism Spectrum Disorder and Autism, sponsored by ProgenaBiome. No longer available at 1 site in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-06-08.

Primary conditionAutistic DisorderRegistry: Autism Spectrum DisorderReclassifiedWhy we changed it
Registry
Autism Spectrum Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Autistic Disorder
Why
  1. The study's listed conditions name Autistic Disorder, a narrower term within Autism Spectrum Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ProgenaBiome · Expanded access

Study type
Expanded access
Access type
Individual patients
Ages
2 Years and older
Sex
All
01

Study summary

Single patient with ASD will be treated with Vancomycin followed by FMT.

Read the detailed description

A single patient with profound ASD will be treated with Vancomycin. This will be followed by fecal microbiota transplant. The patient will be followed for one year.

02

Conditions studied

  • Autism Spectrum Disorder
  • Autism

Browse trials for

Keywords

  • Fecal Transplant
03

In context

Autistic Disorder Reclassified

1,030 studies on the registry are indexed under Autistic Disorder; 266 are open to participants now.

Browse Autistic Disorder studies →

Lead sponsor

ProgenaBiome is the lead sponsor of 47 studies on the registry; 2 are open to participants now.

Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Autism Spectrum Disorder
  2. Parent or Legally Authorized Representative willing and able to provide
  3. A reliable caregiver who can report side effects and communicate effectively with the research team
  4. Stable medications in the two months prior to enrollment
  5. Currently receiving interventions in the community/school for ASD
  6. If female and of , must be willing to utilize at least one highly effective method of for the duration of the study. This includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. Subjects not of will be exempt (e.g. , surgically sterilized)
  7. If male, and partner is of childbearing potential, must be willing to utilize at least one highly effective method of birth control for the duration of the study. This includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. Subjects not of reproductive potential will be exempt (surgically sterilized)

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant, nursing, or intend to become pregnant during the study period.
  2. Subjects whose caregivers are unable/unwilling to cooperate with the protocol requirements.
  3. Subject will be excluded who are suffering with Rett syndrome and Childhood Disintegrative Disorder.
  4. Other serious co-morbid medical disorders affecting brain function and behaviour, including uncontrolled seizures.
  5. Subjects unable to refrain from taking non-study antibiotics for the period of the study.
  6. Subjects diagnosed with cancer, except small localized basal cell carcinoma.
  7. Subjects known to abuse alcohol or drugs.
  8. Subjects who have undergone gastric bypass or total colectomy, or who are scheduled for these procedures.
  9. Infection with .
  10. Infection with or C.
  11. Allergy to benzodiazepine.
  12. Inability to stop loperamide, diphenoxylate/atropine, or cholestyramine before the study
  13. Unable to stop opiate treatment unless on a stable dose including PRN dosing, and no dose increase planned for the duration of the study
  14. Known positive stool cultures for enteropathogens including, but not limited to Shigella, Salmonella, and Campylobacter within 30 days before enrollment.
  15. Known stool studies positive for ova and/or parasites in 30 days prior to enrollment.
  16. Planned travel outside United States during study period.
  17. to vancomycin
  18. Renal insufficiency
  19. Colitis
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

  • BiologicalFecal Microbiota Transplant; Vancomycin

    Subject will be treated with vancomycin followed by fecal microbiota transplant

    Also known as: FMT, vancomycin

06

Where to request access

1 site
  • Ventura Clinical Trials
    Ventura, California 93003, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT04878718
Lead sponsor
ProgenaBiome
Responsible party
Sponsor
First posted
May 7, 2021
Last update
Jun 8, 2025

Study contacts

Sabine Hazan, MD
study director · ProgenaBiome
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion